Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.52
OFIX's Cash to Debt is ranked higher than
60% of the 377 Companies
in the Global Medical Devices industry.

( Industry Median: 6.28 vs. OFIX: 1.52 )
OFIX' s 10-Year Cash to Debt Range
Min: 0.05   Max: 7.59
Current: 1.52

0.05
7.59
Equity to Asset 0.73
OFIX's Equity to Asset is ranked higher than
76% of the 358 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. OFIX: 0.73 )
OFIX' s 10-Year Equity to Asset Range
Min: 0.36   Max: 0.78
Current: 0.73

0.36
0.78
F-Score: 4
Z-Score: 4.86
M-Score: -3.92
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -1.27
OFIX's Operating margin (%) is ranked higher than
59% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 6.25 vs. OFIX: -1.27 )
OFIX' s 10-Year Operating margin (%) Range
Min: -49.44   Max: 29.29
Current: -1.27

-49.44
29.29
Net-margin (%) -6.37
OFIX's Net-margin (%) is ranked higher than
55% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 4.82 vs. OFIX: -6.37 )
OFIX' s 10-Year Net-margin (%) Range
Min: -43.98   Max: 34.01
Current: -6.37

-43.98
34.01
ROE (%) -8.22
OFIX's ROE (%) is ranked higher than
55% of the 365 Companies
in the Global Medical Devices industry.

( Industry Median: 5.79 vs. OFIX: -8.22 )
OFIX' s 10-Year ROE (%) Range
Min: -113.11   Max: 33.7
Current: -8.22

-113.11
33.7
ROA (%) -6.03
OFIX's ROA (%) is ranked higher than
56% of the 380 Companies
in the Global Medical Devices industry.

( Industry Median: 3.09 vs. OFIX: -6.03 )
OFIX' s 10-Year ROA (%) Range
Min: -40.72   Max: 23.53
Current: -6.03

-40.72
23.53
ROC (Joel Greenblatt) (%) -2.14
OFIX's ROC (Joel Greenblatt) (%) is ranked higher than
61% of the 379 Companies
in the Global Medical Devices industry.

( Industry Median: 12.55 vs. OFIX: -2.14 )
OFIX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -115.25   Max: 76.32
Current: -2.14

-115.25
76.32
Revenue Growth (%) -12.10
OFIX's Revenue Growth (%) is ranked higher than
53% of the 278 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. OFIX: -12.10 )
OFIX' s 10-Year Revenue Growth (%) Range
Min: -12.1   Max: 22.1
Current: -12.1

-12.1
22.1
EBITDA Growth (%) -46.80
OFIX's EBITDA Growth (%) is ranked higher than
51% of the 249 Companies
in the Global Medical Devices industry.

( Industry Median: -3.70 vs. OFIX: -46.80 )
OFIX' s 10-Year EBITDA Growth (%) Range
Min: -46.8   Max: 60.2
Current: -46.8

-46.8
60.2
» OFIX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

OFIX Guru Trades in Q1 2013

Diamond Hill Capital 496,008 sh (New)
David Dreman 305,324 sh (New)
Columbia Wanger 725,000 sh (unchged)
Steven Cohen Sold Out
Mario Gabelli 87,975 sh (-1.7%)
Jim Simons 156,078 sh (-9.82%)
Arnold Schneider 19,484 sh (-34.03%)
» More
Q2 2013

OFIX Guru Trades in Q2 2013

Richard Snow 45,035 sh (New)
Joel Greenblatt 125,677 sh (New)
Diamond Hill Capital 682,278 sh (+37.55%)
Arnold Schneider 20,484 sh (+5.13%)
Columbia Wanger Sold Out
Mario Gabelli 87,375 sh (-0.68%)
David Dreman 258,537 sh (-15.32%)
Jim Simons 40,279 sh (-74.19%)
» More
Q3 2013

OFIX Guru Trades in Q3 2013

Arnold Schneider 141,068 sh (+588.67%)
Richard Snow 103,815 sh (+130.52%)
Jim Simons 92,179 sh (+128.85%)
Diamond Hill Capital 751,286 sh (+10.11%)
Mario Gabelli 93,625 sh (+7.15%)
Joel Greenblatt Sold Out
David Dreman Sold Out
» More
Q4 2013

OFIX Guru Trades in Q4 2013

Jim Simons 179,179 sh (+94.38%)
Mario Gabelli 98,325 sh (+5.02%)
Richard Snow 94,045 sh (-9.41%)
Arnold Schneider 112,857 sh (-20%)
Diamond Hill Capital 372,646 sh (-50.4%)
» More
» Details

Insider Trades

Latest Guru Trades with OFIX

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
David Dreman 2013-09-30 Sold Out 0.17%$21.55 - $28.58 $ 30.6526%0
Joel Greenblatt 2013-09-30 Sold Out 0.14%$21.55 - $28.58 $ 30.6526%0
Joel Greenblatt 2013-06-30 New Buy0.14%$26.19 - $35.76 $ 30.652%125677
David Dreman 2013-03-31 New Buy0.29%$35.87 - $39.94 $ 30.65-19%305324
Joel Greenblatt 2012-12-31 Sold Out 0.16%$36.47 - $45.52 $ 30.65-22%0
Joel Greenblatt 2012-09-30 New Buy0.16%$40.25 - $44.9 $ 30.65-27%53003
Joel Greenblatt 2012-03-31 Sold Out 0.09%$34.28 - $42.92 $ 30.65-18%0
Joel Greenblatt 2011-12-31 Add 174.1%0.06%$30.84 - $36.03 $ 30.65-9%21048
Joel Greenblatt 2011-09-30 Reduce -37.89%0.03%$33.61 - $44.52 $ 30.65-21%7679
Joel Greenblatt 2011-06-30 Reduce -46.81%0.11%$32.92 - $42.22 $ 30.65-18%12364
Joel Greenblatt 2011-03-31 Add 28.46%0.05%$28.6 - $32.91 $ 30.650%23246
Mario Gabelli 2011-03-31 Reduce -55.18%0.02%$28.6 - $32.91 $ 30.650%102350
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.80
OFIX's P/B is ranked higher than
77% of the 355 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. OFIX: 1.80 )
OFIX' s 10-Year P/B Range
Min: 0.77   Max: 3.17
Current: 1.8

0.77
3.17
P/S 1.40
OFIX's P/S is ranked higher than
74% of the 372 Companies
in the Global Medical Devices industry.

( Industry Median: 2.74 vs. OFIX: 1.40 )
OFIX' s 10-Year P/S Range
Min: 0.31   Max: 3.87
Current: 1.4

0.31
3.87
PFCF 15.60
OFIX's PFCF is ranked higher than
85% of the 179 Companies
in the Global Medical Devices industry.

( Industry Median: 27.48 vs. OFIX: 15.60 )
OFIX' s 10-Year PFCF Range
Min: 6.45   Max: 654.78
Current: 15.6

6.45
654.78
EV-to-EBIT 20.40
OFIX's EV-to-EBIT is ranked higher than
62% of the 293 Companies
in the Global Medical Devices industry.

( Industry Median: 20.91 vs. OFIX: 20.40 )
OFIX' s 10-Year EV-to-EBIT Range
Min: 6.8   Max: 131.2
Current: 20.4

6.8
131.2

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 28.10
OFIX's Price/Net Current Asset Value is ranked lower than
77% of the 174 Companies
in the Global Medical Devices industry.

( Industry Median: 9.10 vs. OFIX: 28.10 )
OFIX' s 10-Year Price/Net Current Asset Value Range
Min: 6.61   Max: 715.65
Current: 28.1

6.61
715.65
Price/Tangible Book 2.20
OFIX's Price/Tangible Book is ranked higher than
77% of the 328 Companies
in the Global Medical Devices industry.

( Industry Median: 4.40 vs. OFIX: 2.20 )
OFIX' s 10-Year Price/Tangible Book Range
Min: 1.67   Max: 104.21
Current: 2.2

1.67
104.21
Price/DCF (Projected) 1.30
OFIX's Price/DCF (Projected) is ranked higher than
79% of the 177 Companies
in the Global Medical Devices industry.

( Industry Median: 1.90 vs. OFIX: 1.30 )
OFIX' s 10-Year Price/DCF (Projected) Range
Min: 0.55   Max: 2.13
Current: 1.3

0.55
2.13
Price/Median PS Value 0.90
OFIX's Price/Median PS Value is ranked higher than
78% of the 338 Companies
in the Global Medical Devices industry.

( Industry Median: 1.10 vs. OFIX: 0.90 )
OFIX' s 10-Year Price/Median PS Value Range
Min: 0.31   Max: 2.14
Current: 0.9

0.31
2.14
Earnings Yield (Greenblatt) 4.90
OFIX's Earnings Yield (Greenblatt) is ranked higher than
69% of the 279 Companies
in the Global Medical Devices industry.

( Industry Median: 4.60 vs. OFIX: 4.90 )
OFIX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.8   Max: 14.7
Current: 4.9

0.8
14.7
Forward Rate of Return (Yacktman) 3.55
OFIX's Forward Rate of Return (Yacktman) is ranked higher than
82% of the 259 Companies
in the Global Medical Devices industry.

( Industry Median: 1.31 vs. OFIX: 3.55 )
OFIX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 2.5   Max: 38.3
Current: 3.55

2.5
38.3

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:OFX.Germany
Orthofix International N.V., is a limited liability company operating under the laws of Curacao. The company is a global medical device company focused on developing and delivering innovative repair and regenerative solutions to the spine and orthopedic markets. Its products are designed to address the lifelong bone-and-joint health needs of patients of all ages, helping them achieve a more active and mobile lifestyle. The Company designs, develops, manufactures, markets and distributes medical equipment used mainly by musculoskeletal medical specialists for spine and orthopedic applications. Its main products are spinal implant products and related human cellular and tissue based products ('HCT/P products') used in surgical procedures, non-invasive regenerative stimulation products used to enhance bone growth and the success rate of spinal fusions and to treat non-union fractures, external and internal fixation devices used in fracture repair, limb lengthening and bone reconstruction. Its products also include bone cement and devices for removal of bone cement used to fix artificial implants. The Company manages its business by its two global business units ('GBUs'), which are comprised of Spine and Orthopedics supported by corporate activities. Spine provides a portfolio of repair and regenerative products that allow physicians to successfully treat a variety of spinal conditions. This global business unit specializes in the design, development and marketing of the Company's spinal repair products along with regenerative stimulation and biologics products used in spine applications. Spine distributes its products through a network of distributors, sales representatives and affiliates. This global business unit uses both direct and distributor sales representatives to sell spine products to hospitals, doctors and other healthcare providers, globally. Orthopedics provides a portfolio of repair and regenerative products that allow physicians to successfully treat a variety of orthopedic conditions unrelated to spine. This global business unit specializes in the design, development and marketing of the Company's orthopedic repair products along with regeneration stimulation and biologics products used in orthopedic applications. Orthopedics distributes its products through a network of distributors, sales representatives and affiliates. This global business unit uses both direct and distributor sales representatives to sell orthopedics products to hospitals, doctors and other healthcare providers, globally. Its regenerative stimulation products compete mainly with similar products marketed by Biomet Spine, a business unit of Biomet, Inc; DJO Incorporated; and the Exogen product line owned by Smith and Nephew plc. and Essex Woodland, a private equity firm. Its spinal implant, HCT/P products, and Trinity Evolution , an HCT/P product from which it derives marketing fees, competes with products marketed by Medtronic, Inc.; De Puy Synth

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide